Company Intelligence
Hansoh Pharmaceutical
翰森制药
HK: 3692Lianyungang, Jiangsu, ChinaFounded 1995
BIOSECURE
No Known BCC Exposure
Hansoh is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure. No 1260H listing.
1
Tracked Deals
4
Therapeutic Areas
3
Modalities
Overview
Hansoh Pharmaceutical (翰森制药) is one of China's most profitable pharmaceutical companies, with a pipeline spanning oncology, CNS, metabolic, and anti-infective diseases. The company has quietly built one of China's strongest CNS pipelines — a therapeutic area where most Chinese biotechs have little presence. Hansoh's GLP-1 receptor agonist portfolio positions it in the global obesity/metabolic drug race alongside Western giants.
Key Facts
- One of the few Chinese pharma companies with significant CNS pipeline (depression, schizophrenia, Alzheimer's)
- GLP-1 receptor agonist portfolio for obesity/metabolic — entering the competitive global race
- Revenue exceeded $3B in 2025 — one of the most profitable Chinese pharma companies
- Strong medicinal chemistry capabilities, primarily small molecule focused
Key Deals
| Partner | Date | Value | Asset |
|---|---|---|---|
| Multiple (in discussions) | 2026 | TBD | CNS and GLP-1 pipeline assets — expected licensing activity in 2026 |
Corporate Structure
Hong Kong-listed. Controlled by founder Zhong Huijuan (钟慧娟), one of China's wealthiest self-made women. No VIE structure. Significant retained earnings funding internal R&D.